Clinical Trial

Salvaged Red Blood Cell Transfusion During Pancreatic Adenocarcinoma Operations

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to prospectively study the safety of salvage red blood cell (sRBC) transfusion during pancreatic surgery. Primary Objective: 1. To summarize rates and timing of septic adverse events (AE) for patients who receive sRBC or aRBC transfusions within 72 hours of peri-operative transfusion. 2. To summarize rates and timing of transfusion related AEs for patients who receive sRBC or aRBC transfusions within 72 hours of peri-operative transfusion. 3. To summarize rates and timing of AEs in the first 7 post-operative days. Secondary Objectives: 1. To summarize the number of units of aRBC transfused post operative day (POD) #0 after sRBC transfusion in the operating room. 2. To summarize the number of units of aRBC transfused POD#1-7 after sRBC transfusion the operating room, in the absence of overt post-operative hemorrhage.
Trial Details
NCT Number NCT07598357
Lead Sponsor NYU Langone Health
Conditions Pancreatic Surgery
Enrollment 40 participants
Start Date 2026-06
Primary Completion 2028-05 (estimated)
Study Completion 2031-06 (estimated)
Updated on ClinicalTrials.gov 2026-05-20